Rheumatology

Biosimilar Business Recap: New Ustekinumab Partnership; Similis Bio Biosimilar Programs; Celltrion Japan Launch

February 23rd 2023

By Skylar Jeremias

Fresenius Kabi announced a global partnership with Formycon for an ustekinumab biosimilar; Similis Bio partners with Novel351K to co-develop 3 biosimilars; and Celltrion Healthcare launched its bevacizumab biosimilar in Japan.

Study: Higher Adherence Rates Among Users of the Remicade vs Infliximab Biosimilars

February 18th 2023

By Deana Ferreri, PhD

Article

An analysis of US claims data found that prevalent (as of 2017) users of the infliximab reference product (Remicade) had the highest adherence rates compared to naïve originator users, prevalent biosimilar users, and naïve biosimilar users over 18 months of follow-up.

Sandoz' Dr Sonia Oskouei Predicts How Adalimumab Biosimilars Can Help Biosimilar Uptake Overall

February 12th 2023

By Skylar Jeremias

Article

Sonia T. Oskouei, PharmD, vice president of biosimilars and specialty at Sandoz, foreshadows how the US market introduction of adalimumab biosimilars could influence future biosimilar entrances and discusses why educational efforts need to be tailored to different specialties and stakeholders.

Phase 4 Study Finds Comparable Safety, Efficacy Between Etanercept Biosimilar, Enbrel for Autoimmune Diseases

February 10th 2023

By Justina Petrullo

Article

The first phase 4 postmarketing surveillance study for SB4 in South Korea as the first approved biosimilar of etanercept demonstrated comparable effectiveness and safety to previous SB4 evidence.

Eye on Pharma: Formycon Aflibercept Data; Sandoz CHMP Nod; Henlius Daratumumab Study

February 8th 2023

By Skylar Jeremias

Article

Formycon shared positive data on its Eylea (aflibercept) biosimilar; Sandoz received a thumbs up from the European Union’s Committee for Medicinal Products for Human Use (CHMP); and Shanghai Henlius Biotech began a phase 1 study for its daratumumab biosimilar candidate.

Vizient Report Predicts Over 3% Inflation Rate for Biologics

February 7th 2023

By Skylar Jeremias

Article

Vizient’s Pharmacy Market Outlook report examined the impact that factors, such as the COVID-19 pandemic and the US market introduction of adalimumab biosimilars, will have on drug prices and the utilization of lower-cost biologics.

Biosimilars Rheumatology Roundup for January 2023—Podcast Edition

February 5th 2023

By Skylar Jeremias

Article

On this episode of Not So Different, we reminisce about the major biosimilar news to come out of the rheumatology field during January 2023, including the launch of the first Humira (adalimumab) biosimilar.

High Treatment Retention Following Biosimilar-to-Biosimilar Switch in Denmark

February 4th 2023

By Skylar Jeremias

Article

A real-world study assessing the aftermath of Denmark implementing a nationwide mandatory switch from one infliximab to another found strong treatment retention rates, demonstrating the safety and tolerability of biosimilar-to-biosimilar switching.

Biosimilar Rheumatology Roundup: January 2023

February 1st 2023

By Skylar Jeremias

Article

This year started off with a bang for rheumatology biosimilars, with several regulatory approvals around the world, new market insight into the global use of biosimilars, and US market introduction of the first rival biosimilar to Humira (adalimumab).

US Welcomes First Adalimumab Biosimilar, Amjevita

January 31st 2023

By Skylar Jeremias

Article

Amgen’s Amjevita (adalimumab-atto) has officially entered the US market, making it the first of potentially 10 biosimilars referencing Humira to launch in 2023.